NF1 Loss

CI-VAR-00002479Explore in graph →CIViC 698

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Peripheral Nerve Sheath Tumor2
NF1 Loss	Bevacizumab + EverolimusCombination	Predictive	B	Does Not Support Sensitivity Response	2	submitted	EID7727 Sporadic and Neurofibromatosis Type 1 (NF1) related refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) showed no significant clinical benefit when treated with Everolimus in Combination with … (full text at CIViC) PMID 31427883 · Widemann et al., 2019 · Open in CIViC	civic
NF1 Loss	JQ1 Compound	Predictive	D	Supports Sensitivity Response	3	accepted	EID1743 BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts PMID 24373973 · Patel et al., 2014 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma3
BRAF V600E AND NF1 Loss	Vemurafenib	Predictive	D	Supports Resistance	3	accepted	EID90 In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors. PMID 24576830 · Nissan et al., 2014 · Open in CIViC	civic
NF1 Loss	Afatinib + CetuximabSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID12435 Loss-of-function of NF1, a tumor suppressor and negative regulator of RAS signaling, is recurrent in melanoma and contributes to MAPK pathway activation. This study demonstrates that NF1 loss in melan… (full text at CIViC) PMID 40494652 · Ibrahim et al., 2025 · Open in CIViC	civic
NF1 Loss	Dabrafenib	Predictive	D	Supports Resistance	3	submitted	EID1957 Taken together with preclinical studies in the mouse model and genetic studies in human melanoma cell lines, these observations further support the hypothesis that NF1/neurofibromin suppression may pl… (full text at CIViC) PMID 23171796 · Maertens et al., 2013 · Open in CIViC	civic

Neuroblastoma1
NF1 Loss	Binimetinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID1956 Low NF1 protein expression correlated positively with responses to binimetinib in neuroblastoma cell lines. PMID 26925841 · Woodfield et al., 2016 · Open in CIViC	civic

Neurofibroma1
NF1 Loss	Trametinib	Predictive	C	Supports Sensitivity Response	2	rejected	EID7265 A 12-year-old child with Neurofibromatosis 1 (NF1) with multiple cutaneous and paraspinal neurofibromas responsible for impaired walking, motor deficiency and pain. A treatment with Trametinib was ini… (full text at CIViC) PMID 30174724 · Papalia et al., 2018 · Open in CIViC	civic